Rhopressa (soln)
| Rhopressa (soln) | |
|---|---|
| DOSAGE | 1 gtt QPM |
| GENERIC | netarsudil dimesylate 0.02% |
| SIZE | 2.5mL |
| INDICATIONS | Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. |
| MECHANISM OF ACTION | Increase aqueous outflow |
| MICROBIOLOGY | Netarsudil is a rho kinase inhibitor, which is believed to reduce IOP by increasing the outflow of aqueous humor through the trabecular meshwork. The exact mechanism is unknown. |
| CONTRAINDICATIONS & WARNINGS | None |
| PEDIATRIC USE | Safety and effectiveness in pediatric patients below the age of 18 years have not been established. |
| PREGNANCY | There are no available data on RHOPRESSA use in pregnant women to inform any drug associated risk; however, systemic exposure to netarsudil from ocular administration is low |
| NOTE | |